Clinical trials: Stent Restenosis
Hyperplasia, Restenosis
Numen Stent Assessment Using OCT Technique in a Single Center Study
This is a prospective single centre Study designed to assess by OCT the effect of NUMEN cobalt-chromium balloon-expandable stent in inducing neointimal hyperplasia in de novo native coronary lesions of patients with Stable Angina…
- Trial name
- NAUTIC (NCT00774917)
- Testing
- Numen
- Where
- 2 sites in Austria
- Volunteers
- 60 people
- Sponsor
- International Biomedical Systems S.p.A.
Coronary Disease, Coronary Artery Disease
The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial
Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation has become the dominant treatment strategy for patients with acute and chronic coronary artery disease (CAD) requiring revascularization.
- Conditions
- Coronary Disease, Coronary Artery Disease, Calcific Coronary Arteriosclerosis, Stent Restenosis
- Trial name
- VICTORY (NCT05346068)
- Testing
- OPN™ NCB Super High Pressure PCI Balloon, Shockwave™ C2 IVL Catheter
- Where
- Switzerland
- Volunteers
- 280 people
- Sponsor
- Luzerner Kantonsspital
In-stent Restenosis
Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)
To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.
- Trial name
- NCT06117150
- Testing
- Drug-eluting Coronary Spur Stent System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- ReFlow Medical, Inc.
Coronary Restenosis
EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
In this study, the safety and efficacy of COMBO TM stent beyond 36 months are assessed, in particular the occurrence of late stent thrombosis and late loss catch-up (restenosis).
- Trial name
- NCT02263313
- Testing
- EGO-COMBO group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The University of Hong Kong
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention
The Efector study is an open, randomized and controlled trial assessing the effect of regular exercise training on endothelial function, inflammatory markers, progression of disease, heart rate variability and mental health in…
- Trial name
- EFECTOR (NCT00469950)
- Testing
- exercise training
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Helse Stavanger HF
Stable Angina, Unstable Angina
A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)
This is a multicentric randomized comparison between paclitaxel-coated balloon angioplasty or paclitaxel-eluting stent implantation in patients with stable or unstable angina with the evaluation of restenosis by Quantitative…
- Trial name
- COMPACT-ISR (NCT01204320)
- Testing
- Paclitaxel-coated Balloon, Paclitaxel-eluting Stent
- Where
- Italy
- Volunteers
- 154 people
- Sponsor
- Ospedale San Donato
Coronary Artery Disease, Coronary Artery Stenosis
A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB CHINA (NCT01923740)
- Testing
- XIENCE V EECSS, Absorb BVS System
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Abbott Medical Devices
Heart Disease, Ischemia
Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis
The purpose of this randomized study is to determine which treatment option, either paclitaxel-eluting balloon, paclitaxel-eluting stent or plain balloon angioplasty is the most effective in the treatment of restenosis after…
- Conditions
- Heart Disease, Ischemia, Restenosis
- Trial name
- ISAR-DESIRE-3 (NCT00987324)
- Testing
- Taxus stent, SeQuent Please, Conventional Balloon Catheter
- Where
- 3 sites in Germany
- Volunteers
- 402 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices
DES In-stent Stenosis
Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon
The aim of the study is to investigate the non-inferiority of the new sirolimus-coated balloon catheters in comparison to the paclitaxel-coated SQP with regard to acute tolerance, safety and efficacy in coronary DES in-stent…
- Trial name
- FIMLIMUSDCB (NCT02996318)
- Testing
- Paclitaxel coated balloon (SeQuent Please), Sirolimus coated balloon
- Where
- 5 sites in Malaysia
- Volunteers
- 50 people
- Sponsor
- InnoRa GmbH
In-stent Restenosis
Safety and Efficacy of Paclitax Coated Balloon in Patients With Coronary In-stent Restenosis (ISR)
The purpose of this observational study was to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter in coronary in-stent restenosis (ISR) patients.
- Trial name
- GENISPIRE (NCT05656118)
- Testing
- Genoss® DCB
- Where
- 10 sites in South Korea
- Volunteers
- 260 people
- Sponsor
- Yonsei University
Coronary Restenosis
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00409981
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital, Saarland
CHD - Coronary Heart Disease, Percutaneous Coronary Intervention
Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis
This study is a prospective, registry trial aimed to compare the clinical and angiographic outcomes of OCT-guided and angiography-guided PCI in patients with coronary DES-ISR.
- Conditions
- CHD - Coronary Heart Disease, Percutaneous Coronary Intervention, In-stent Restenosis
- Trial name
- NCT03809754
- Testing
- Percutaneous Coronary Intervention under OCT, Percutaneous Coronary Intervention under Angiography
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Treatment of Symptomatic Ischemic Heart Disease
The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)
Two consecutive cohorts of subjects were each treated with the CoStar stent loaded with a different paclitaxel dose regimen. The first 145 subjects (Arm I), enrolled between 20 January 2004 and 26 May 2004, were treated with 10…
- Trial name
- NCT00974181
- Testing
- Conor Medsystems COSTAR™ stent (10 µg Paclitaxel), Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)
- Where
- Italy
- Volunteers
- 282 people
- Sponsor
- Cordis US Corp.
Coronary Disease, Coronary Artery Disease
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT00531011)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System, TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Coronary Restenosis
Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES
Hypothesis: Angioplasty with a novel paclitaxel-coated balloon (PCB; Agent, Boston Scientific) with citrate-based excipient will be non-inferior to conventional paclitaxel-coated balloon with iopromide excipient (PCB) for the…
- Trial name
- ISAR-DESIRE 3A (NCT02367495)
- Testing
- PCB
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Compare the Safety and Effectiveness of Genoss® DCB and SeQuent® Please NEO in Chinese Patients with Coronary ISR
The purpose of this study is to evaluate the safety and effectiveness of Genoss® DCB by demonstrating non-inferiority in patients with in-stent restenosis (ISR) compared with a product of the same category (Sequent® Please NEO).
- Trial name
- NCT04767022
- Testing
- Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB), Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Genoss Co., Ltd.
Patients Above 18 Years
Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
The Below-Study is a randomized, prospective mono-centre trial on the efficacy and safety the adjunctive use of a GP IIb/IIIa antagonist for prevention of early reocclusion in arterial below-the knee interventions.
- Trial name
- NCT00163254
- Testing
- abciximab, stent and drug eluting stent
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Angioplasty, Transluminal, Percutaneous Coronary, Percutaneous Coronary Intervention
To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study
The investigators sought to discover which one of the following strategies is the safest for patients undergoing percutaneous coronary intervention: paclitaxel-coated balloon+Genous stent; Genous stent; drug eluting stent…
- Trial name
- EREMUS (NCT00870038)
- Testing
- Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent, Percutaneous coronary intervention: Uncoated balloon + Genous stent, Percutaneous coronary intervention: Drug eluting stent (Taxus stent)
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Ospedale della Misericordia